Article: Epinastine HCl 0.05% Shows Rapid Efficacy and Control of Ocular Allergy Symptoms for Up to 12 Hours; Research Could Offer New Relief to the Many Ocular Allergy Patients Suffering From Symptoms Such as Swelling, Redness and Itching.

SAN DIEGO, April 29 /PRNewswire/ -- Data from a new study to evaluate the efficacy of epinastine (HCl 0.05%) were presented today at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Ft. Lauderdale, Fla. Epinastine is the most recent addition to a new generation of ocular allergy treatments that features a multi-action mechanism consisting of topical ophthalmic antihistamine, with mast cell-stabilizing and anti-inflammatory properties.

"Ocular allergy affects approximately 22 million Americans. Symptoms such as itching, redness, and swelling often cause significant discomfort and in some cases can lead to severe complications and ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!